

**Original Research Article**

**GENDER CHARACTERISTICS AND DISSIMILARITIES IN FEMALES HAVING  
HEART FAILURE WITH MILDLY REDUCED EJECTION FRACTION**

**ABSTRACT**

**BACKGROUND:** The clinical features, epidemiology, pathogenesis & management of heart failure with mildly reduced ejection fraction ( HFmrEF ) differ in gender-specific dissimilarities like hormonal impact, anthropometry, pregnancy-related changes, comorbidities, specific diseases in women (incidence of HFpEF is higher in females whereas HFrEF is more common in males). This study aims to identify gender differences with meaningful clinical implications in females diagnosed with heart failure with HFmrEF.

**METHODOLOGY:** 130 patients with HFmrEF patients aged more than 18 years without any evidence of sepsis were included in this study

**RESULTS:** Females represented around 26% ( 35 patients ) of the entire study population, with a mean age of 64 years & upper-middle SES. Mean BMI was 25.6 (class I obesity ), and 58% & 37% had NYHA class II & III at presentation, respectively. CAD was noted in 57%, and the mean values of haemoglobin & NT-proBNP were 10.8 gm% & 11145pg/ml, respectively. The mean EF was 44% & 35% had moderate PH. Readmission rates were 28% in 1 year ( 17 % in males ). Around 90 % were on anti-platelets, statins, and beta-blocker therapy; diuretics/MRA's were used in < 40% ( compared to 31% in males ), whereas 30% & 16% were on SGLT2I &

ARNI respectively( 42% & 20 % males ). An improvement in LV function was noted in 30%, and AKI/CKD/ADHF/UTI were the major deterrents to initiating core HF therapy.

## **CONCLUSION**

This study addressed the under-represented female population with HFmrEF sharing similar clinical features as their gender counterparts but with a higher proportional prevalence of anaemia, PH, CKD, readmission rates, and inadequate core HF treatment.

**KEYWORDS:** Heart failure, Mildly reduced ejection fraction, Heart failure admission, Gender difference.

## **ABBREVIATIONS**

HFmrEF - Heart failure with mildly reduced ejection fraction, SES- Socioeconomic class, HF- heart failure, AKI- acute kidney injury, CKD- chronic kidney disease, CAD - coronary artery disease, PH- pulmonary hypertension

## **INTRODUCTION**

HF is likely to be a significant cause of death and disability in developing countries & along with the increased incidence of vascular diseases and the persistence of pre-transitional diseases such as Rheumatic heart disease (RHD) and cardiomyopathy(1). HF is a clinical syndrome characterized by typical symptoms such as breathlessness, leg swelling, and easy fatigability, which may be accompanied by signs such as raised jugular venous pressure (JVP), pulmonary crackles, and peripheral oedema caused by structural and functional cardiac

abnormalities, resulting in a reduced cardiac output and/or elevated intracardiac pressures at rest or during stress (2)

Heart failure affects approximately 26 million people worldwide. In the United States alone, it was responsible for an estimated \$13 billion in health expenditure in 2012 (more than 10% of total CVD health expenditure (3). HF is a major health issue in India, with demographic projections estimating an alarming rise in the prevalence of HF in India, ranging from 1.3 to 23 million (4). Coronary artery disease (CAD) & Rheumatic heart disease (RHD) are the two major causes of heart failure in India, according to research from Trivandrum and hospital-based studies (5).


The 2016 ESC heart failure guidelines defined a new category of HF with 40–49% EF as heart failure with mid-range EF (HFmrEF) (2). Its overall prevalence in the HF spectrum is 10–25% (6). HFmrEF is a milder variety than HFrEF, and cardiovascular risk is lower, like in HFpEF, than in those with HFrEF. Even though EF is a continuous variable, its distinct phenotype is supported with renaming of HFmrEF to HF with mildly reduced EF by Savarese et al.(7).

The Trivandrum Heart Failure Registry, India (THFR) enrolled 1205 patients, while another research from the All India Institute of Medical Sciences (AIIMS) tested 10,163 individuals from six villages in Northern India for HF (5). These are the two biggest studies that have lately been released in India, where HF with preserved and reduced EF was discussed in both studies. However, neither study considered mildly reduced EF.

## **1. METHODOLOGY**

This study is a tertiary care hospital-based prospective observational study with 130 confirmed cases of heart failure population over 18 years after excluding sepsis. This study population was aimed at female subsets with a study duration of 1 year. Samples were collected from in-hospital and OPD records of heart failure patients. Symptomatology was assessed by Minnesota Living With Heart Failure Questionnaire (8), Boston criteria, and ESC guidelines for heart failure diagnosis(2). Patient characteristics, clinical history & examination, and echocardiographic profiles were initially studied. They were followed during a hospital stay while readmission rates, mortality rates over a period of 12 months along with clinical profile, available laboratory parameters like CBC, LFT, RFT, iron studies, NT-pro BNP, TSH, echocardiographic assessment of ejection fraction using modified Simpson's method, angiographic evidence for heart failure worsening were analyzed as shown in table 1. All data were instilled chronologically and were calculated statistically by SPSS Version 23.0. Subgroup analysis was done for statistical significance.

**TABLE 1 : METHODOLOGY AND STUDY FLOW**



## 1.1. STATISTICAL ANALYSIS


All categorical variables are expressed as percentages. All continuous variables are expressed as mean+ SD if they are normally distributed. Comparison of those variables was done either by independent sample t-test. All other variables with no normal distribution will be expressed as median (interquartile range). A comparison of those was made by Mann Whitney U or Kruskal Wallis H tests. The Chi-square test is used for comparing categorical variables. Data entry is done in an MS Excel spreadsheet. Data analysis was carried out by SPSS Version 23.0. All analyses will be significant statistically when all P values <0.05.

**1.2. Ethical Clearance:** Institutional Ethical Committee approval was obtained.

## 2. RESULTS

After taking informed consent from a total of 130 patients with HF and their calculated LVEF ranging from 41-49 %. They were enrolled in our study between July 2021 to December 2022. This study's total population of females was 35 patients (26%, as shown in Figure 1) with a mean age of around 64 years.

**Figure 1 :** Gender proportion of HFmrEF patients under study.



They belonged to upper-middle socioeconomic status and had increased awareness about their illness. The mean BMI noted was 25.6 as compared to 27 in males. Even though the general observation of more comorbid illnesses associated with obesity with regards to more hypoventilation disease, sleep disorders, and poor metabolic control there was limited significance in comparing HF episodes and pulmonary hypertension. The overweight class of patients had more than mild and moderate PAH. But NYHA class and increasing BMI scale had more statistical significance.

The average values of hemoglobin in this group of patients was 10.8gm%, urea-40mg %, creatinine -1.2mg%, sodium-135.6mEQ/L, mean potassium-4.3mEQ/L, median HbA1C

recorded was 5.4%. Around 89% patients had TSH values of which 96% were euthyroid, 8% were hypothyroid & 3 % were hyperthyroid. There was statistical significance in comparing the anemia severity with number of prior HF admission (P value < 0.05)

On analyzing the reasons to avoid core drugs such as beta blockers were ADHF, recent ACS causing subnormal heart rate, and associated bronchial asthma/COPD/ peripheral artery disease. However, beta-blockers were initiated pre-discharge. However, ACEi/ARB and MRA's were not started or withheld in view of AKI/acute on chronic kidney disease /CKD (21 patients) & dyselectrolytemia in 8 patients. SGLT2i was initiated in only 30% of female patients either due to worsening CKD and mild symptomatic/asymptomatic status. Other insignificant reasons such as sleep disorders, contrast-induced AKI, immediate postoperative period, awaiting a surgical/ intervention, and aortic valve pathology have played a minor role.

CAD as a causative factor was noted in 57% of the study population and 40% of them underwent revascularization in the past. Around 85 % of them had their LIMA grafted to LAD & the remainder were grafted with saphenovenous graft to LAD. Very few were grafted with radial artery graft. Total arterial revascularization was attempted in 10 % of patients.

On comparing the NYHA class and CKD patients, it was found that CKD patients were more in the NYHA class IV than non CKD patients and it was statistically significant. Also CKD patients had more frequent heart failure hospitalization. Other detailed results of this study are given in Table 2.

**TABLE 2:** Results of the study representing female versus male patients having heart failure with mildly reduced ejection fraction

<b>BASELINE CHARACTERISTICS (n= 130)</b>	<b>PREVALENCE ( Females vs Males)</b>
Total female population	26 % (35 female patients ) vs 74% (105 male patients )
The mean age of the population (in years)	64 vs 67
Socio-economic status	Upper middle > lower middle
Type 2 diabetes mellitus	65% vs 70%
Systemic hypertension	68% vs 76%
Mean BMI	25.6 vs. 27
Mean hemoglobin (in grams %)	10.8 vs. 12.6
Mean NTproBNP (40% patients) (pg/mL)	11145 vs. 9899
Atrial arrhythmia	Less than 3% of patients
Hypothyroidism	15%
CAD	57% vs 66%
Acute/ chronic kidney disease	30%
NYHA class II the t presentation	58%
NYHA class III at presentation	37%
Mean ejection fraction in echocardiogram	44% vs 45%
Moderate pulmonary hypertension	35% vs 15%
Readmission rates	28% in 1 year ( 17 % in males )- p-value 0.04
<b>TREATMENT-RELATED DIFFERENCES</b>	

Antiplatelets	90%
Beta-blockers	86%
Loop diuretics	40% vs 30%
Mineralocorticoid receptor antagonists	40% vs 28%
Nitrates, other vasodilators, other antianginals	18%
ARNI (Angiotensin receptor blocker + neprilysin inhibitor )	16% vs 20%
SGLT2i (sodium-glucose-like transporter 2 inhibitors)	30% vs 42%
<b>PROGNOSIS</b>	
Improving LVEF	28% vs 35%
Compliance with medical treatment	90% vs 92%
HF-related death	2.85% vs. 4.6%

### 3. DISCUSSION:

Heart failure (HF) is a global pandemic(4) with its prevalence increasing on the scale of the growing population as suggested by Conrad et al(14). The most important triggers are the ageing population, better survival after suffering myocardial infarction & improved treatment, and survival of patients with HF(15). Despite all advances in cardiac disease management, HF prognosis could not be improved due to revascularisation dependency in HF patients. The presence of HF with normal EF was recognized as a reason for this diagnostic delay. Then recognition of HFpEF has greatly aided in the increased diagnosis of HF.

In the 2016 ESC HF guidelines (2), HF with mid-range EF was an additional entry with separate clinical characteristics. This update was made for ongoing HF studies with an attempt to categorize patients, as studies were lacking compared for HFrEF (EF <40%) and HFpEF (EF  $\geq$ 50%). Extensive contemporary research supports the evidence that HFmrEF, as an intermediate category between HFrEF and HFpEF, shares distinct similarities & the term HF with 'mildly reduced' EF was also proposed by authors over the past 2 years(7).

Our study was aimed at identifying the phenotypic characteristics of an unexplored subset of heart failure, i.e., Heart failure with mildly reduced ejection fraction, thereby identifying the triggers, gender differences, treatment aspects, and prognosis. Analysis of our study results and comparison with other relevant studies are discussed below.

### **3.1. Biochemical aspects**

Biochemical analysis revealed that almost all patients had euthyroid status, mean haemoglobin in their lower normal range, and mean creatinine of 1.6mg %. NTproBNP was available in 40% of female patients with a mean value was 7970pg/mL.

### **3.2. Echocardiographic aspects**

Among the study population of 35 female patients, after 12 months of follow-up, 28% of patients had improvement in LVEF ( HFpEF/HF with an improved EF category), whereas 23 % of patients had a reduction in LVEF with the transition to HFrEF/ HFmrEF - Detoriated. Around 49% of patients were still in HFmrEF range LVEF with minor improvement (HFmrEF- Unchanged). Around 4 patients with new onset HFmrEF features were due to ACS (HFmrEF- no

prior EF determination). The contribution of mitral regurgitation and RV dysfunction was less in this study than in the ESC-HF-LT registry (9).

### **3.3. Treatment aspects:**

Around 90% of patients were adequately treated with antiplatelets, statins, and beta blockers. Only 40% of patients were on ACEi, mineralocorticoid receptor antagonists & diuretics for symptomatic relief. Nearly 40%, 16% & 30% of female patients were treated with diuretics, ARNI, and SGLT2i, respectively, for the acute HF episode suggesting the milder symptomatic status of the hospitalized female patients. This data is similar to the Savarese et al. (10) and ESC-HF-LT registry (9).

### **3.4. Prognosis:**

Among the study population of 35 female patients after 12 months of follow-up, the mortality rate was (2.8%) in patients with HFmrEF. The death in that 1 case was due to long-standing heart failure with multiple comorbidities.

### **3.5. Clinical predictors of incident HFmrEF**

In this study, we found that old age, hypertension and its treatment, overweight BMI subset, CAD, and revascularization predicted incident HF as per Savarese et al. (11). It also helped to analyze the older age patients, male sex, CKD, overweight BMI subset, NYHA class, mean EF, elevated NT-proBNP, prior myocardial infarction, and revascularization which are the key determinants predicting worsening of HFmrEF ( $P < 0.05$  for all).

### **3.6. All-cause mortality rates for HFmrEF**

After HF onset, there was one death per 35 female patients compared to 2 deaths among 105 male patients with HFmrEF. The all-cause mortality rate was 497 events per 10,000 person-years among participants with HFmrEF as per Bhambhani et al. meta-analysis (6). Hence this study needs a further long-term follow-up for the foreseeable mortality as expressed in other larger studies.

Patients with HF had readmission rates of 28% within 12 months, suggesting that HFmrEF has the highest chance of being readmitted. According to Cheng et al., HFmrEF has a higher rate of cardiac readmissions, followed by the HFpEF subset and HFrEF(12). According to Laursen et al. meta-analysis, HFmrEF readmission rates were significantly lower than HFrEF readmission rates, whereas HFpEF readmission rates were higher (13). Our study group showed a readmission rate of about 28% vs 17% in males, which is close to the global studies, which shows the similarity between HFrEF.

Our study demonstrates that age, sex, blood pressure, diabetes mellitus, and previous myocardial infarction anticipate incident HFmrEF. As suggested by Bhambhani et al., incident HFmrEF has identical poor survival to those with incident HFrEF but a mildly improved better survival than with incident HFpEF (6). The study's Strengths, Recommendations and limitations are illustrated in Table 3

**Table 3 shows the strength, limitations, and recommendations of this study**

Components	Comments
Strength	<ul style="list-style-type: none"> <li>• HFmrEF study compares the female Asian population and their outcomes with the prevailing poor scientific data.</li> <li>• Identifying reversible risk factors more common in females, such as BMI, anaemia &amp; non-adherence to GDMT, can prevent deterioration in HFmrEF(9).</li> </ul>
Limitations	<ul style="list-style-type: none"> <li>• Recruitment bias if patients were transitioning EF ranges.</li> <li>• Misclassification due to unstandardized operator variability, lack of core lab, and a single operator.</li> <li>• Restricted clinical history after HF event due to HF device therapy, arrhythmia treatment, and cross referrals.</li> <li>• Financial constraints in using cardiac biomarkers for HF.</li> <li>• Lack of prolonged follow-up period for better prognostication.</li> </ul>
Recommendations	<ul style="list-style-type: none"> <li>• There is a need for a multi-centric study in India to reduce heart failure mortality, worsening more rapidly than cancer mortality.</li> <li>• Long-term follow-up for developing a structured protocol for heart failure management across major centers in India.</li> <li>• Serial echocardiographic follow-up with CPET (cardiopulmonary exercise testing) to identify the subset of patients with improved ejection fraction.</li> </ul>

#### **4. CONCLUSION:**

HFmrEF is a transitioning stage in the natural course of heart failure that differs from other phenotypes of HF subsets. Male sex, elderly, overweight BMI subset, NYHA class at presentation, presence of CAD & CKD predicted incident and worsening HFmrEF. Morbidity and mortality were higher in hospitalized patients with HFmrEF than ambulatory patients. Among the individual subset of HFmrEF, there exists a gender difference in baseline characteristics, disease presentation for early identification of specific triggers and targets of HFmrEF, expedited medical management for avoiding readmission rates, and mortality aiming to improve LV ejection fraction.

#### **5. REFERENCES:**

1. Prabhakaran D, Jeemon P, Roy A. Cardiovascular Diseases in India: Current Epidemiology and Future Directions. *Circulation*. 2016 Apr 19;133(16):1605–20.
2. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J*. 2016 Jul 14;37(27):2129–200
3. Savarese G, Lund LH. Global public health burden of heart failure. *Cardiac failure review*. 2017 Apr;3(1):7.
4. Harikrishnan S, Sanjay G, Anees T, Viswanathan S, Vijayaraghavan G, Bahuleyan CG, Sreedharan M, Biju R, Nair T, Suresh K, Rao AC. Clinical presentation,

- management, in-hospital and 90-day outcomes of heart failure patients in Trivandrum, Kerala, India: the Trivandrum Heart Failure Registry. *European journal of heart failure*. 2015 Aug;17(8):794-800.
5. Harikrishnan S, Bahl A, Roy A, Mishra A, Prajapati J, Nanjappa MC, et al. National Heart Failure Registry, India: Design and methods. *Indian Heart J*. 2019;71(6):488–91.
  6. Bhambhani V, Kizer JR, Lima JAC, van der Harst P, Bahrami H, Nayor M, et al. Predictors and outcomes of heart failure with mid-range ejection fraction. *Eur J Heart Fail*. 2018 Apr;20(4):651–9.
  7. Savarese G, Stolfo D, Sinagra G, Lund LH. Heart failure with mid-range or mildly reduced ejection fraction. *Nature Reviews Cardiology*. 2022 Feb;19(2):100-16.
  8. Catchpool M, Ramchand J, Hare DL, Martyn M, Goranitis I. Mapping the Minnesota Living with Heart Failure Questionnaire (MLHFQ) onto the Assessment of Quality of Life 8D (AQoL-8D) utility scores. *Qual Life Res*. 2020 Oct;29(10):2815–22.
  9. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, Ferrari R, Piepoli MF, Delgado Jimenez JF, Metra M, Fonseca C. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. *European journal of heart failure*. 2016 Jun;18(6):613-25.
  10. Savarese G, Kishi T, Vardeny O, Adamsson Eryd S, Bodegård J, Lund LH, Thuresson M, Bozkurt B. Heart failure drug treatment—inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF). *Heart Failure*. 2023 Jan 1;11(1):1-4.

11. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GM, Coats AJ. Global burden of heart failure: a comprehensive and updated review of epidemiology. *Cardiovascular research*. 2022 Dec 1;118(17):3272-87.
12. Cheng RK, Cox M, Neely ML, Heidenreich PA, Bhatt DL, Eapen ZJ, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. *Am Heart J*. 2014 Nov;168(5):721–30.
13. Lauritsen J, Gustafsson F, Abdulla J. Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis. *ESC Heart Fail*. 2018 Aug;5(4):685–94.
14. Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. *The Lancet*. 2018 Feb 10;391(10120):572–80
15. Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. *Circ J*. 2013;77(9):2209–17.